MedPage Today November 26, 2024
— Federal government would pick up about three-fourths of the cost for Medicaid coverage
Medicare and Medicaid recipients with obesity would have access to coverage of pricey GLP-1 receptor agonists like semaglutide (Wegovy) or tirzepatide (Zepbound) under a regulation proposed Tuesday by the Centers for Medicare & Medicaid Services (CMS).
Current law “excludes drugs used for weight loss from Medicare prescription drug coverage,” CMS administrator Chiquita Brooks-LaSure said on a call with reporters. “This exclusion makes these drugs an optional drug benefit for Medicaid programs. Historically, this has meant that drugs used for weight loss, even when used for treatment of individuals with obesity, have been excluded from Medicare prescription drug coverage for Medicaid,” with some states covering them and...
Today's Sponsors
Today's Sponsor